Iovance Biotherapeutics Announces Participation in Upcoming Scientific Congresses

Core Insights - Iovance Biotherapeutics, Inc. is focused on developing novel tumor infiltrating lymphocyte (TIL) therapies for cancer patients, with pre-clinical data for IOV-5001 and five-year outcomes data for lifileucel to be presented at upcoming major oncology meetings [1][6] Group 1: Company Overview - Iovance aims to be a global leader in TIL therapies, utilizing the human immune system to target diverse cancer cells [3] - The company has achieved FDA approval for Amtagvi, the first T cell therapy for a solid tumor indication, and is committed to continuous innovation in cell therapy [3] Group 2: Upcoming Presentations - Pre-clinical data for IOV-5001 will be presented at the 2025 AACR Annual Meeting, highlighting its enhanced antitumor efficacy [1][6] - Five-year outcomes from the C-144-01 study of lifileucel in advanced melanoma will be shared at the 2025 ASCO Annual Meeting [1][6] - A trial-in-progress poster for lifileucel in frontline advanced non-small cell lung cancer will also be presented at the ASCO meeting [6] Group 3: Events and Engagement - Iovance will host a panel discussion featuring key opinion leaders in melanoma on May 31, 2025, with a live and archived webcast available on the company's website [6]